Abstract
Background:
Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation.
Methods:
A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17.
Results:
KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain.
Conclusion:
The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Benzenesulfonates / therapeutic use*
-
Female
-
Humans
-
Imatinib Mesylate
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / pathology
-
Middle Aged
-
Mutation
-
Neoplasm Metastasis
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Piperazines / therapeutic use*
-
Proto-Oncogene Proteins c-kit / genetics
-
Pyridines / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / pathology
-
Sorafenib
Substances
-
Antineoplastic Agents
-
Benzamides
-
Benzenesulfonates
-
Phenylurea Compounds
-
Piperazines
-
Pyridines
-
Pyrimidines
-
Niacinamide
-
Imatinib Mesylate
-
Sorafenib
-
Proto-Oncogene Proteins c-kit